clinical trial · NCT05767346
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Obstructive Hypertrophic Cardiomyopathy (oHCM)Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Placebo to match aficamtenMetoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)Placebo to match metoprolol succinate
brief summary
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
started
Jun 20, 2023
primary completion
Feb 28, 2025
completion
Mar 28, 2025
last updated
Jun 9, 2026
official title
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol